In the pivotal investigator-initiated, phase II Trial of PARP Inhibition in Prostate Cancer (TOPARP-A), the antitumor activity of olaparib 400 mg twice a day was evaluated in patients with metastatic, castration-resistant prostate cancer (CRPC) previously treated with chemotherapy and novel hormonal therapy (28). This evidence concerns the gene PARP1 and prostate cancer.